Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
15.63
+0.89 (6.04%)
At close: Aug 13, 2025, 4:00 PM
15.07
-0.56 (-3.58%)
Pre-market: Aug 14, 2025, 9:01 AM EDT
Arcutis Biotherapeutics Revenue
Arcutis Biotherapeutics had revenue of $81.50M in the quarter ending June 30, 2025, with 164.13% growth. This brings the company's revenue in the last twelve months to $263.47M, up 99.50% year-over-year. In the year 2024, Arcutis Biotherapeutics had annual revenue of $196.54M with 229.74% growth.
Revenue (ttm)
$263.47M
Revenue Growth
+99.50%
P/S Ratio
7.45
Revenue / Employee
$770,365
Employees
342
Market Cap
1.87B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ARQT News
- 5 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - Arcutis Biotherapeutics, Inc. (ARQT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 12 days ago - Arcutis: Leveraging Zoryve's Success While Positioning For Pipeline Expansion - Seeking Alpha
- 21 days ago - Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 - GlobeNewsWire
- 6 weeks ago - Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction - Seeking Alpha
- 7 weeks ago - Arcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis - GlobeNewsWire
- 7 weeks ago - Arcutis Biotherapeutics: Another Approval Under Their Belt - Seeking Alpha